Cortechs.ai | Prediction of amyloid positivity using automated segmentation
RSNA 2025
Contact
RSNA 2026

Prediction of amyloid positivity using automated segmentation

  • Category: Published research
  • Disease: Mild cognitive impairment

Prediction of amyloid positivity in mild cognitive impairment using fully automated brain segmentation software

The objective of this study was to assess the predictive ability of regional volume information provided by fully automated brain segmentation software for cerebral amyloid positivity in mild cognitive impairment (MCI). (2020).

[button]Download[/button]

  • Topic: Published research

More Resources

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

Prostate Cancer Awareness Month
  • 4 mins

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 2 mins

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

,

Cortechs.ai | Prediction of amyloid positivity using automated segmentation
  • 3 mins

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

,

View our insights
Scroll to Top